LY-334370
LY-334370 is a selective serotonin 5-HT1F receptor agonist of the triptan and piperidinylindole families which was under development by Eli Lilly and Company for the treatment of migraine headaches. The drug showed efficacy in a phase II clinical trial but further development was halted due to toxicity detected in animals. It is closely related to tryptamines like the psychedelic drug dimethyltryptamine, but is not technically a tryptamine itself and is instead a piperidinylindole similarly to naratriptan.